Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
07/08/2026 03:29
BUZZ-Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat ** Hong Kong-listed shares of Zai Lab 9688.HK jump 14.7% to HK$16.67, their highest point since May 7
** Stock posts its biggest intraday pct rise since October 2024
** Stock is top pct gainer in Hang Seng Biotech Index .HSBIO, which climbs 1%
** The biopharmaceutical products developer posts revenue of $106.31 million for the second quarter ended June. That compared with analysts' forecast of $103.81 million, and first-quarter revenue of $95.6 million
** Company reported a loss of $50.83 million for the second quarter, compared with first-quarter loss of $51.02 million
** YTD, Hong Kong stock up 21.8%, while benchmark Hang Seng Index .HSI down 0.6%
(Reporting by Donny Kwok)
Recent news on Zai Lab
See all newsBrief: Zai Lab Agrees To Issue To Investors Aggregate Of 11.3 Million ADSs
Zai Lab's Hong Kong shares hit three-month high on quarterly revenue beat
Brief: U.S. FDA Grants Orphan Drug Designation To Zai Lab’S Dll3-Targeting Adc Zocilurtatug Pelitecan (Zoci) For The Treatment Of Neuroendocrine Carcinomas (Necs)
Brief: Goldman Sachs Group's Long Position In Zai Lab Decreases On May 14, HKEX Filing Shows
Brief: Zai Lab Receives U.S. FDA Fast Track Designation For Zocilurtatug Pelitecan (Zoci)